NCT03014804 (disregard the references to a "lung tumor" vaccine. This is a GBM trial and those references were a mistake which should be fixed soon.
Another trial will soon be opening for newly diagnosed GBM testing the Agenus Prophage vaccine (HSPPC-96) in combination with pembrolizumab. This is a randomized phase 2 trial and unfortunately one arm will be treated with standard of care + pembrolizumab + placebo, while the other arm gets standard + pembrolizumab + vaccine.
Another trial of HSPPC-96 for newly diagnosed GBM reported some results at ASCO 2015. Patients with high PD-L1 expression had median survival of 18 months, while patients with low PD-L1 expression had an amazing median survival of 44.7 months. There is thus very good rationale to combine this vaccine with a PD-1 inhibitor such as pembrolizumab.
How do you find out if you have high or low PD-L1 expressed? Is it in a Foundation One Report?
ReplyDeleteMike B
This test is one where you're looking for the presence or absence of a protein (PD-L1), probably by immunohistochemistry. FoundationOne is specifically gene sequencing, so its not on FoundationOne reports. Caris does PD-L1 testing. You could also try asking your oncologist at the institution where the tumor sample is stored if they could run that test.
DeleteWe did ours thru foundation bur looks like they used an outside lab. IHC
ReplyDeleteYou're right it does seem that Foundation Medicine now offers PD-1 and PD-L1 testing, though this is separate from the FoundationOne test also offered by Foundation Medicine.
Deletehttp://investors.foundationmedicine.com/releasedetail.cfm?releaseid=985071
I was unable to find information about PD-1 or PD-L1 testing in the main section of the Foundation Medicine website (the above was from the investors section).